Wegovy Cost & Access in the US (2026)

Wegovy is the brand of semaglutide approved specifically for weight management, and its price is one of the most-searched numbers in US healthcare. The honest answer is that the “price” you see quoted — roughly $1,350 a month — is a list price that almost nobody actually pays. What you pay comes down to one question: how are you getting it? This page walks through every realistic 2026 route, from full cash to a $25 copay, including the brand-new oral pill and the Medicare change that arrives mid-year.

Note: This page covers Wegovy specifically — the weight-loss brand. For the molecule-level view across all semaglutide products, see semaglutide cost; for the diabetes brand, see Ozempic cost.

The list price (and why it’s mostly a fiction)

In 2026 the list price of Wegovy is about $1,350 per month, and Novo Nordisk has set the same headline figure for both the once-weekly injection pen and the new once-daily pill. Retail cash prices at standard pharmacies float in roughly the $1,200–$1,400 range depending on the pharmacy and any discount card applied.

That number is the starting point before any program, not the real-world cost. It functions a bit like a hospital’s chargemaster rate: it’s what shows up if you walk in with no insurance and no savings program, but Novo Nordisk has spent the last year building cheaper self-pay channels precisely so fewer people land on it. The practical takeaway is to treat $1,350 as a ceiling you can almost always get below, not as the price.

Self-pay through NovoCare: the big 2026 change

The most important development for cash-paying patients is NovoCare Pharmacy, Novo Nordisk’s own direct-to-patient channel. It bypasses the usual retail markup, ships to your door (or supports pharmacy pickup), and posts fixed self-pay prices that are dramatically lower than list.

For the injection pen, NovoCare self-pay is $349 per month for the standard strengths (the doses you titrate up through, to the 2.4 mg maintenance dose), and $399 per month for the high-dose Wegovy HD 7.2 mg pen. There is also a new-patient introductory offer: $199 per month for your first two monthly fills (for the 0.25 mg and 0.5 mg starting doses), available through June 30, 2026, after which the price steps up to the standard $349.

For the oral pill, self-pay starts at $149 per month for the 1.5 mg and 4 mg strengths. The 4 mg promotional price holds through August 31, 2026, then rises to $199 for that strength; higher pill strengths run around $299 per month. Novo Nordisk has marketed the pill as the most affordable self-pay entry point it has ever offered for a weight-loss GLP-1.

A key catch with self-pay: because you’re paying cash, that money generally does not count toward your insurance deductible or out-of-pocket maximum, and government beneficiaries are excluded from these offers. Prices, eligibility, and the promotional windows can also change at any time — Novo Nordisk reserves the right to modify or cancel the programs.

With commercial insurance: the savings offer

If you have commercial (private) insurance that covers Wegovy, the manufacturer’s savings offer can bring your share down to as little as $25 per month. The savings are capped — generally up to $100 off a one-month fill, $200 off two months, and $300 off three months — so the $25 figure assumes your plan is already absorbing most of the cost and the card covers the rest of a modest copay.

Two limits matter. First, the savings offer is commercial-only: if you’re on Medicare, Medicaid, TRICARE, the VA, or any other government plan, you cannot use it. Second, it generally applies to on-label use — Wegovy prescribed for weight management or its approved cardiovascular indication — which is usually how Wegovy is written anyway, but it’s worth confirming with your prescriber and pharmacy.

The harder reality in 2026 is that commercial coverage for weight loss has been shrinking. Many employer and commercial plans exclude GLP-1s for obesity entirely, or gate them behind prior authorization. When coverage exists, expect requirements like a BMI of 30 or higher (or 27-plus with a weight-related condition), documentation of prior weight-loss attempts, step therapy, and specialty-tier placement. We cover the appeals and prior-authorization process in depth on the GLP-1 insurance coverage page.

The Wegovy coverage advantage: it’s not only a weight-loss drug

Here’s the wrinkle that makes Wegovy’s cost picture genuinely different from the diabetes-brand semaglutide story. Wegovy isn’t approved only for weight loss — it also carries an FDA indication to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established heart disease who have obesity or overweight, plus a more recent indication in MASH (metabolic-associated steatohepatitis, a serious liver condition).

Those non-weight-loss indications are coverage doors. A plan — including Medicare Part D — that won’t pay for a GLP-1 prescribed “for weight loss” can still cover Wegovy when it’s prescribed for cardiovascular risk reduction or MASH, because those aren’t in the excluded weight-loss category. This is the structural reason Wegovy tends to be more reliably covered than Ozempic-for-weight-loss: the prescription can be anchored to a covered medical indication. For a side-by-side on the two brands, see Ozempic vs Wegovy.

Medicare in 2026: the GLP-1 Bridge

For years, federal law has barred Medicare Part D from covering any drug prescribed solely for weight loss. That hasn’t changed — but a major workaround arrives mid-2026.

Starting July 1, 2026, the Medicare GLP-1 Bridge lets eligible Part D enrollees access Wegovy (both the injection and the pill) for obesity at a flat $50 monthly copay. The program runs through December 31, 2027 as a time-limited demonstration, meant to bridge to a possible permanent model in 2028. It’s run outside the normal Part D structure through a central CMS processor, which has practical consequences:

• The $50 copay is fixed regardless of which Part D benefit phase you’re in.
• It does not count toward your Part D deductible or the 2026 out-of-pocket cap (about $2,100).
• Extra Help / low-income subsidies don’t apply to it.
• Eligibility is clinical — your prescriber attests you met the BMI criteria when therapy started, and prior authorization goes to the CMS system rather than your private carrier.

Outside the Bridge, ordinary Medicare Part D still covers Wegovy for its cardiovascular and MASH indications at standard plan cost-sharing — so a Medicare patient with qualifying heart disease may have a covered path regardless of the Bridge. We keep the full mechanics on GLP-1 insurance coverage.

The oral pill: a new, cheaper entry point

In December 2025 the FDA approved the Wegovy pill (once-daily oral semaglutide, 25 mg), the first oral GLP-1 approved for weight management, and it launched in the US in early January 2026. For people who want to avoid injections, it’s a genuine alternative — and, at $149/month self-pay for the lower strengths, currently the cheapest legitimate brand entry point into Wegovy.

A few honest caveats. The pill is taken once daily rather than weekly, and oral semaglutide has historically come with empty-stomach timing requirements, so it asks more of your routine than the weekly pen. In its pivotal trial the oral version produced strong but somewhat lower average weight loss than the highest-dose injectable. And the promotional $149 price on the 4 mg strength is time-limited (through August 31, 2026). It’s a real option, not automatically the right one — the choice between pen and pill is about cost, convenience, and tolerance together.

If none of those fit: patient assistance

If you’re uninsured or underinsured and your household income is low enough, Novo Nordisk’s Patient Assistance Program (PAP) may provide Wegovy at no cost. It’s income-tested and separate from the savings offer and self-pay programs. HSA and FSA funds can also be used for Wegovy when it’s prescribed for a qualifying medical condition, effectively paying with pre-tax dollars — keep your prescription and receipts for those claims.

What about compounded semaglutide?

You’ll see telehealth ads quoting $99–$299/month for “compounded semaglutide” as a Wegovy alternative. Be careful here: the FDA shortage that made mass-market compounding legal ended in early 2025, and broad 503A/503B compounding of semaglutide has largely wound down. Only a narrow, patient-specific 503A path remains, and cost or convenience is not a qualifying reason for it. Compounded product is not FDA-approved Wegovy, quality varies, and the legal ground has shifted. The full picture is on is compounded semaglutide/tirzepatide still legal?.

Putting it together

There is no single Wegovy price — there’s a price for your situation:

• Commercial insurance covers it: likely $25/month with the savings offer.
• No coverage, want the lowest cash price: NovoCare self-pay — $199 (new-patient pen, through June 30) or $149 (pill) to start, $349 standard pen.
• On Medicare with obesity: $50/month via the GLP-1 Bridge from July 1, 2026.
• On Medicare with heart disease or MASH: standard Part D coverage for those indications.
• Low income, uninsured: possibly $0 through the patient assistance program.

The list price grabs headlines, but for most people in 2026 it’s the least relevant number on the page. Figure out which route applies to you first; the cost follows from that. Pricing and program windows shift frequently, so treat the figures here as current as of the lastUpdated date and confirm with NovoCare, your plan, or your prescriber before you commit.